Company
Information
![[Previous Page]](prevpage.gif){kind=small}
![[Next Page]](nextpage.gif){kind=small}
![[Up]](up.gif){kind=small}
![[Home Page]](homepage.gif){kind=small}
![[Mail]](mail.gif){kind=small}
![[Contents]](contents.gif){kind=small}
ImmunoScience,
Inc. is a Nevada Corporation initially founded by Sateesh Apte, M.D. in
July, 1995, for the purpose of researching, developing and marketing innovative
products to the biomedical industry. Seed capital and first stage financing was
obtained via private placement from a group of investors, which has funded the
development of the company and its products thus far. The Company’s exciting
main product, Contre-Vir™, a live recombinant therapeutic vaccine and a
potential cure for HIV infection is pending further clinical trials after a
very successful pilot trial. In the interim, the company has focused its
efforts on testing and manufacturing of its saliva based diagnostic tests for
HIV, Syphilis, Hepatitis B & C, Drugs of Abuse and Tuberculosis. With
aggressive efforts, a worldwide distributor network has been established and is
working diligently to obtain regulatory approvals and establish sales. The
network has achieved success in Russia where the Russian Ministry of Health has
approved Company’s Salivax™ tests after en extensive evaluation by Russia’s
foremost institutes and Company expects to sell 800,000 test kits in Russia
during 2000. The distributor for Western Africa has managed to obtain orders
for 1,100,000 tests from a major pharmaceutical company operating in Africa.
Company has also been assured of an order for 1,000,000 test kits in the region
of Southern Africa for 2000. Other tests are also being made available to
distributors in the Nordic countries for rapid detection of pregnancy,
ovulation and infections such as chlamydia to be distributed via Sweden’s only
drug store chain “Apoteket” and its sisters in Norway and Denmark. Company
expects to fully develop and sell about 9 additional different test kits during
2000 and obtain FDA approval for 2-5 of them. Company’s distributor for
Peoples’ Republic of China expects to get approval for the test kits from the
Ministry of Health during the first half of 2000 followed by significant
product sales in the second half. The
products are currently being tested or are in the planning phases of testing in
several countries in South America, Central America and Asia.
In 1999 and 2000, Company
received approval for sale of its Salivax™ products in Russia, Ghana, South
Africa and Nigeria. The products were also taken up by the World Health
organization for testing which is being conducted at the Institute of Tropical
Medicine in Antwerp, Belgium.
In India, Company has forged
a relationship with <a href=”http://www.wockhardtin.com”>Wockhardt,
Ltd. </a> to market the products as point-of-care devices. Wockhardt,
Ltd. is a major pharmaceutical company with sales in Africa, south Asia and
Southeast Asia.
Company’s scientists have
visited several countries in Africa and have executed a Memorandum of
Understanding with JCRC in Uganda for beginning clinical trials of Contre Vir™
and have received letters of intent from Tanzania, The Noguchi Institute in
Ghana and from South Africa. These trials are to begin soon.
1. Dr. Sateesh N.
Apte, M.D., President & CEO: A Neurologist
in Pleasanton, California and founder of the Company. Dr. Apte had his undergraduate
education in India and he completed his residencies at Boston University
Medical Center, Harvard Medical School, UC Davis Medical Center and also
completed a fellowship at Stanford University Medical Center. In addition to
raising funds for the activities of ImmunoScience, he has also actively
participated in all the other vital functions including Research, Development,
Website Design, Engineering, Graphic Design, Regulatory Aspects and Foreign
Research Planning. One of his hidden strengths is his ability to speak several
languages fluently, which allows easier access in 3/4th of the world. Prior to
starting with ImmunoScience, Dr. Apte had a private practice in San Ramon and
Pleasanton, California.
2. Robert J Nagy,
CPA, Vice President, Finance & CFO: Mr. Nagy, formerly CFO of
a publicly held company in South
Carolina, received his accounting degree from the University of South
Carolina. He has extensive private
practice experience as a CPA, having served as a Senior Tax Manager with
McGladrey & Pullen and managing partner of a large local CPA firm in
Columbia, South Carolina. He has
extensive experience in corporate budgeting, financial analysis, operations,
systems implementation and long-range strategic planning. He has experience in all aspects of SEC
reporting and compliance. More
recently, as a partner at Financial Resources Group, LLC, he has been involved
with operations planning and consulting, and debt and equity financing for
early and mid-stage companies. Mr.
Nagy is a member of the American
Institute of CPAs and the South Carolina Association of CPAs.
3. Victor Martin,
Ph.D., Vice President, Manufacturing and Regulatory Affairs: Dr.
Martin obtained his undergraduate and graduate degrees in London, UK and
obtained his Ph.D. from St. Bartholomew’s Hospital Medical School in London,
UK. He has extensive experience in biotechnology companies, including
Manufacturing, Quality Control, Quality Assurance, Regulatory Affairs and
Project Management. Prior to ImmunoScience, Dr. Martin was employed by BioGenex
laboratories in San Ramon, another biotechnology company. Dr. Martin has
extensive experience with FDA requirements with respect to Quality Systems and
application process including 510-K and new device applications.
4. Quirin Miranda, Ph.D., Vice President, Product Development: Dr. Miranda received his
Ph.D. in Microbiology from the University of Manchester, UK and has held
important management and research positions at various biotechnology and
pharmaceutical firms including Schering, Organon Technika, DDI pharmaceuticals,
Food Sciences Corp and Sepragen. He has several US patents to his credit and
his expertise promises to be a major asset to ImmunoScience, Inc.
5. John Morken,
Esq., Director: Mr. Morken has been with the company since
shortly after its inception. He has a vary diverse background in all areas of
business including Corporate and Commercial law, Real Estate, Acquisitions,
Sales, Leasing and Governmental Affairs. Mr. Morken has been in the private
practice of Law for the past several years.
6. Lorenzo
Crutchfield, Director: Mr. Crutchfield has been with the company for
four years and has an extensive background in Insurance and Telecommunications
enterprises. After the founder, he is the second largest shareholder of the
company. Mr. Crutchfield was the Chairman of the Board of Transworld
Telecommunications, Inc. for seven years before the company was sold to Sprint
Corp.
7. John Washington,
Secretary and Director: Mr. Washington, a Majority Partner in Carale
Cellular Partners has been with the company for over 2 years. Prior to
overseeing the formation and final disposition of Carale Cellular Partners to a
major Eastern telephone company, Mr. Washington was with Kaiser Aerospace doing
work on such projects as C4 and D5 Trident missiles and MX missiles. His
special expertise in plastics, manufacturing and process control is expected to
be a great asset to ImmunoScience. He is also an important and sizable
shareholder of ImmunoScience, Inc.
8. David A. Kekich,
Vice President, Public and Investor Relations: Mr.
Kekich, is also a president of Red Tree International. Mr. Kekich is an
investor, financial planner and has a wide range on expertise in Investment
Banking, Venture Capital, Capital Structuring and Exit Strategies for Venture
Capital Investors. Mr. Kekich has been associated with Dr. Apte and
ImmunoScience, Inc. since February 1995.
Scientific Advisory Board
The scientific advisory board has been formed to
assist the Company in conducting its research and product innovations. The
following members form the board:
1. Armin Ramel,
Ph.D., Chair: Dr. Ramel has a Ph.D. in Physical Chemistry from
University of Basel, Switzerland. Dr. Ramel has an extensive experience in the
biotechnology and pharmaceutical industries. He was in charge of product
development at Hoffman La Roche in Switzerland and the United States and was a
director of process development at Genentech Corporation. His most recent
appointment was as a Vice-President of Product Development at Scios, Corp.
2. Milton R.J. Salton,
Ph.D., D.Sc, F.R.S.: Dr. Salton has a Ph.D. from the University of
Cambridge in UK and he has been an eminent microbiologist well known on both
sides of the Atlantic, Australia and Brazil. He is a fellow of the prestigious
Royal Society. He has been a faculty member of various notable universities
including Cambridge, University of California at Berkeley, Temple University
and University of Adelaide. He is a member of over a dozen prestigious
professional societies and has served on the editorial board of about 10 peer
review scientific journals. A well-published and accomplished researcher, Dr.
Salton has over 150 scientific publications in the scientific literature.
3. Edwin Lenette,
M.D., Ph.D.: Dr. Lenette is fondly called the “father of virology” by
his peers. He has received a Doctor of Medicine and a Ph.D. from the University
of Chicago and has had a distinguished career spanning several decades
encompassing academia, government and private industry. In addition to
receiving over 20 awards and honors, he has been well-published in the medical
literature, having about 500 publications to his name. He has also written
chapters in about 50 different textbooks on microbiology and virology. He
brings a very special input to the Company because he has been involved with
practically every single vaccine project ever undertaken in science.
4. George Luedemann,
Ph.D.: Dr. Luedemann has a Ph.D. in microbiology and has been well known
in the academia and industry. He worked for Schering corp. where he invented
Gentamycin, the first antibiotic useful against gram negative organisms, an
invention almost at par with the discovery of penicillin.
5. Dr. Ronald H.
Gray, MD, MSc, DTM&H. : is a
scientific advisor to ImmunoScience, Inc. Dr. Gray is a Professor at Johns
Hopkins University School of Public Health and is a Director of the Center for
VDT and Health Research. He has extensive contributions to the medical literature
in the fields of epidemiology and public health. He has conducted research in
various Asian and African countries, Australia, UK and of course, the United
States. Dr. Gray became aware of ImmunoScience’s therapeutic vaccine while
consulting with the honorable health minister of Uganda, Dr. Chrispus Kiyonga
and has been optimistically excited about the prospect of a therapeutic
vaccine.
6. Dr. Ellen Jo Baron, Ph.D.: Dr.
Baron has been at Stanford since 1997, serving on the clinical faculty in the
infectious diseases division. She directs the Stanford Clinical
Microbiology/Virology Laboratory. Dr. Baron is an associate professor of pathology at the Medical Center effective
April 2000 through March 2005. Dr. Baron received her PhD in medical
microbiology with minors in biochemistry and bacteriology in 1981 from the
University of Wisconsin, Madison. She worked in southern California as
consulting director, microbiology and immunology, with Endocrine Sciences and
as a consulting microbiologist with several area hospitals. She served as an
adjunct associate professor at UCLA and as a clinical associate professor at
the University of Southern California. In 1997 Baron received the prestigious
Alice C. Evans Award from the American Academy of Microbiology in recognition
of her scientific accomplishments, including the discovery of a previously
unknown anaerobic bacterium. This year she garnered the BioMerieux Sonnenwirth
Award from the American Society of Microbiology. She is a fellow of the
American Academy of Microbiology and of the Infectious Diseases Society of
America. She currently chairs the American Board of Medical Microbiology. Dr.
Baron also serves on the advisory board of the US FDA related to diagnostic devices.
|
How to contact us |
|
|
Our Products |
|
|
Home Page |
|
|
Home Page |
|
|
Send EMail to
ImmunoScience, Inc. |
|
|
ImmunoScience, Inc. Contents |
Please note that ImmunoScience's products are the
subject of many US and International patent applications. This document does
not convey any rights to develop, manufacture, use or sell anything described
herein.